Search for: "Matter of S. G. v B. G."
Results 601 - 620
of 2,552
Sorted by Relevance
|
Sort by Date
4 Aug 2008, 7:08 pm
" In the Matter of L.A.R., Janel R. v. [read post]
6 Jun 2023, 8:29 am
The background of Sackett v. [read post]
6 Jun 2023, 8:29 am
The background of Sackett v. [read post]
6 Jun 2023, 8:29 am
The background of Sackett v. [read post]
24 Mar 2014, 11:55 am
Key Statutes R.C. 2953.08(G)(2) The court hearing an appeal under division (A), (B), or (C) of this section shall review the record, including the findings underlying the sentence or modification given by the sentencing court. [read post]
29 Apr 2018, 7:41 am
See Rolen v. [read post]
17 Jun 2011, 9:53 am
The judge therefore denied Demiro’s Rule 41(g) motion. [read post]
18 Mar 2011, 1:23 pm
§1396r-8(g)(l)(B)(i), and 42 C.F.R §423.100).Neither Cetrotide for granulose cell tumor or Increlex for muscular dystrophy appeared in these compendia. [read post]
9 Jul 2015, 7:10 am
Casey B. [read post]
29 Sep 2015, 2:12 pm
Code § 1030(g). [read post]
13 Mar 2007, 10:55 pm
§ 924(e)(2)(B)(ii); see also United States v. [read post]
25 Sep 2017, 3:32 pm
The Court disagrees.As an initial matter, the defendants make unduly short shrift of Spokeo. [read post]
7 Sep 2010, 3:13 pm
The restriction confirmed by the courts in Whaley v Lord Watson 2000 (later confirmed by the House of lords). [read post]
11 Feb 2016, 7:34 am
CODE ANN. 171.053(a)(b) (West 2011). [read post]
10 Jul 2015, 4:00 am
The Appellate Division said that "[b]ecause of the significant due process implications of the statute, strict compliance with its procedures is required. [read post]
19 May 2019, 1:05 pm
CES Publ’g Corp. v. [read post]
26 Jun 2016, 2:30 pm
(The guidelines are contained here: 4-1.5(b) of the Rules Regulating the Florida Bar; Lee Eng’g & Constr. [read post]
26 Jun 2016, 2:30 pm
These are the guidelines authorities: 4-1.5(b) of the Rules Regulating the Florida Bar; Lee Eng’g & Constr. [read post]
31 Oct 2006, 5:46 pm
Claim 1 was for ‘Use of the neurotoxin component of Botulinium toxin for the manufacture of a medicament for the treatment of pain associated with muscle activity or contracture', while Claim 5 covered ‘Use according to any one of the preceding claims, wherein the neurotoxin component of Botulinium type A, B, C, D, E, F or G'. [read post]
22 Nov 2006, 8:46 am
Yonkers, Inc. v. [read post]
